These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

777 related articles for article (PubMed ID: 27590317)

  • 1. DNA Repair in Prostate Cancer: Biology and Clinical Implications.
    Mateo J; Boysen G; Barbieri CE; Bryant HE; Castro E; Nelson PS; Olmos D; Pritchard CC; Rubin MA; de Bono JS
    Eur Urol; 2017 Mar; 71(3):417-425. PubMed ID: 27590317
    [TBL] [Abstract][Full Text] [Related]  

  • 2. DNA Repair Deficiency Is Common in Advanced Prostate Cancer: New Therapeutic Opportunities.
    Dhawan M; Ryan CJ; Ashworth A
    Oncologist; 2016 Aug; 21(8):940-5. PubMed ID: 27317574
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impact of mutations in homologous recombination repair genes on treatment outcomes for metastatic castration resistant prostate cancer.
    Carlson AS; Acevedo RI; Lim DM; Gulati R; Gawne A; Sokolova AO; Cheng HH; Nelson PS; Montgomery RB; Yu EY; Schweizer MT
    PLoS One; 2020; 15(9):e0239686. PubMed ID: 32997692
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Targeting DNA Repair: The Role of PARP Inhibition in the Treatment of Castration-Resistant Prostate Cancer.
    Castro E; Mateo J; Olmos D; de Bono JS
    Cancer J; 2016; 22(5):353-356. PubMed ID: 27749330
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Defective DNA repair mechanisms in prostate cancer: impact of olaparib.
    De Felice F; Tombolini V; Marampon F; Musella A; Marchetti C
    Drug Des Devel Ther; 2017; 11():547-552. PubMed ID: 28280302
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Genetic Aberrations of DNA Repair Pathways in Prostate Cancer: Translation to the Clinic.
    Ghose A; Moschetta M; Pappas-Gogos G; Sheriff M; Boussios S
    Int J Mol Sci; 2021 Sep; 22(18):. PubMed ID: 34575947
    [TBL] [Abstract][Full Text] [Related]  

  • 7. BRCA Mutations in Prostate Cancer: Assessment, Implications and Treatment Considerations.
    Shah S; Rachmat R; Enyioma S; Ghose A; Revythis A; Boussios S
    Int J Mol Sci; 2021 Nov; 22(23):. PubMed ID: 34884434
    [TBL] [Abstract][Full Text] [Related]  

  • 8. PARP Inhibitors and Prostate Cancer: To Infinity and Beyond BRCA.
    Risdon EN; Chau CH; Price DK; Sartor O; Figg WD
    Oncologist; 2021 Jan; 26(1):e115-e129. PubMed ID: 32790034
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Genetic aberrations of homologous recombination repair pathways in prostate cancer: The prognostic and therapeutic implications.
    Saeidi H; Bakrin IH; Raju CS; Ismail P; Saraf M; Khairul-Asri MG
    Adv Med Sci; 2023 Sep; 68(2):359-365. PubMed ID: 37757663
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy of Poly(ADP-ribose) Polymerase Inhibitors by Individual Genes in Homologous Recombination Repair Gene-Mutated Metastatic Castration-Resistant Prostate Cancer: A US Food and Drug Administration Pooled Analysis.
    Fallah J; Xu J; Weinstock C; Gao X; Heiss BL; Maguire WF; Chang E; Agrawal S; Tang S; Amiri-Kordestani L; Pazdur R; Kluetz PG; Suzman DL
    J Clin Oncol; 2024 May; 42(14):1687-1698. PubMed ID: 38484203
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Circulating Tumor DNA Testing for Homology Recombination Repair Genes in Prostate Cancer: From the Lab to the Clinic.
    Cimadamore A; Cheng L; Massari F; Santoni M; Pepi L; Franzese C; Scarpelli M; Lopez-Beltran A; Galosi AB; Montironi R
    Int J Mol Sci; 2021 May; 22(11):. PubMed ID: 34073818
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Role of PARP Inhibitors in the Treatment of Prostate Cancer: Recent Advances in Clinical Trials.
    Xia M; Guo Z; Hu Z
    Biomolecules; 2021 May; 11(5):. PubMed ID: 34066020
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Identification of Novel Biomarkers of Homologous Recombination Defect in DNA Repair to Predict Sensitivity of Prostate Cancer Cells to PARP-Inhibitors.
    Criscuolo D; Morra F; Giannella R; Cerrato A; Celetti A
    Int J Mol Sci; 2019 Jun; 20(12):. PubMed ID: 31242618
    [TBL] [Abstract][Full Text] [Related]  

  • 14. PROREPAIR-B: A Prospective Cohort Study of the Impact of Germline DNA Repair Mutations on the Outcomes of Patients With Metastatic Castration-Resistant Prostate Cancer.
    Castro E; Romero-Laorden N; Del Pozo A; Lozano R; Medina A; Puente J; Piulats JM; Lorente D; Saez MI; Morales-Barrera R; Gonzalez-Billalabeitia E; Cendón Y; García-Carbonero I; Borrega P; Mendez Vidal MJ; Montesa A; Nombela P; Fernández-Parra E; Gonzalez Del Alba A; Villa-Guzmán JC; Ibáñez K; Rodriguez-Vida A; Magraner-Pardo L; Perez-Valderrama B; Vallespín E; Gallardo E; Vazquez S; Pritchard CC; Lapunzina P; Olmos D
    J Clin Oncol; 2019 Feb; 37(6):490-503. PubMed ID: 30625039
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Homologous Recombination Repair Deficiency in Metastatic Prostate Cancer: New Therapeutic Opportunities.
    Piombino C; Pipitone S; Tonni E; Mastrodomenico L; Oltrecolli M; Tchawa C; Matranga R; Roccabruna S; D'Agostino E; Pirola M; Bacchelli F; Baldessari C; Baschieri MC; Dominici M; Sabbatini R; Vitale MG
    Int J Mol Sci; 2024 Apr; 25(9):. PubMed ID: 38731844
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Genetic aberrations in DNA repair pathways: a cornerstone of precision oncology in prostate cancer.
    Lozano R; Castro E; Aragón IM; Cendón Y; Cattrini C; López-Casas PP; Olmos D
    Br J Cancer; 2021 Feb; 124(3):552-563. PubMed ID: 33106584
    [TBL] [Abstract][Full Text] [Related]  

  • 17. PARP Inhibitors in Prostate Cancer—The Preclinical Rationale and Current Clinical Development.
    Virtanen V; Paunu K; Ahlskog JK; Varnai R; Sipeky C; Sundvall M
    Genes (Basel); 2019 Jul; 10(8):. PubMed ID: 31357527
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Genetic biomarkers to guide poly(ADP-ribose) polymerase inhibitor precision treatment of prostate cancer.
    Varnai R; Sipeky C
    Pharmacogenomics; 2020 Oct; 21(15):1101-1115. PubMed ID: 33021139
    [TBL] [Abstract][Full Text] [Related]  

  • 19. PARP inhibitors as a new therapeutic option in metastatic prostate cancer: a systematic review.
    Ratta R; Guida A; Scotté F; Neuzillet Y; Teillet AB; Lebret T; Beuzeboc P
    Prostate Cancer Prostatic Dis; 2020 Dec; 23(4):549-560. PubMed ID: 32367009
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Integrating PARP Inhibitors Into Advanced Prostate Cancer Therapeutics.
    Gong J; Posadas E; Bhowmick N; Kim H; Daskivich T; Gupta A; Sandler H; Kamrava M; Zumsteg Z; Freedland S; Figlin R
    Oncology (Williston Park); 2021 Mar; 35(3):119-125. PubMed ID: 33818052
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 39.